PHARMACEUTICAL SERVICES

STRATEGY | DEVELOPMENT | DELIVERY

We understand poor pre-formulation studies may lead to delays in pre-clinical and clinical development programs. With our world-leading expertise in development of methods for inhaled drug product characterisation, we can provide the solid foundation required for successful transition of early phase development programs through to clinical.

Orally inhaled and nasal drug products are complex systems that are highly dependent on interactions between device and formulation components. Our INTERHALE technologies offer a range of tailored and robust formulation development solutions for all types of pMDIs and DPI device platforms.

Nanopharm was founded on its advanced analytical characterisation services and its understanding of how input material physico-chemical and mechanical properties affect product specification, functionality and stability of orally inhaled and nasal drug products.

Contact

Stay Connected

RECEIVE REGULAR HELPFUL INFORMATION FROM US

Leave this field empty if you’re human:

Privacy StatementNanopharm is responsible for controlling any personal data it receives under the General Data Protection Regulation. Our Privacy Policy governs how we collect, process and use personal data on our website.